10-QPeriod: Q2 FY2024

BeOne Medicines Ltd. Quarterly Report for Q2 Ended Jun 30, 2024

Filed August 7, 2024For Securities:ONCBEIGF

Summary

Beigene, Ltd. (ONC) reported a significant increase in total revenues for the second quarter of 2024, reaching $929.2 million, a 56% rise compared to the same period last year. This growth was primarily driven by a substantial 107% increase in BRUKINSA sales, totaling $637.4 million globally, with particularly strong performance in the U.S. and Europe. Despite the revenue growth, the company reported a GAAP net loss of $120.4 million for the quarter. The company also highlighted its strategic advancements, including the opening of its new U.S. facility in Hopewell, New Jersey, and progress in its pivotal programs for sonrotoclax and BGB-16673. While the company's operating loss narrowed significantly, it continues to invest heavily in research and development and selling, general, and administrative expenses to support its product pipeline and commercialization efforts. Investors should note the significant decline in collaboration revenue due to the termination of prior agreements, which is more than offset by the robust growth in product revenue. The company's cash position remains strong at $2.6 billion, though it is managing a substantial amount of debt, with over $851 million due within the next 12 months. Beigene appears to be on a positive trajectory with its key product, BRUKINSA, gaining market share and driving substantial revenue growth, but continued investment in R&D and commercial expansion will be crucial for future profitability.

Financial Highlights

49 data points
Beta

Revenue

$929.17M

85.1% Gross Margin

Net Income

-$120.41M

-13.0% Net Margin

EPS (Diluted)

$-0.09

Total Assets

$5.71B

Cash & Equivalents

$2.59B

Free Cash Flow

-$205.54M

Financial Statements
Beta
Revenue$929.17M
Gross Profit$791.03M
R&D Expenses$454.47M
SG&A Expenses$443.73M
Operating Expenses$898.20M
Operating Income-$107.16M
Interest Expense$13.23M
Net Income-$120.41M
EPS (Basic)$-0.09
EPS (Diluted)$-0.09
Shares Outstanding (Basic)1.36B
Shares Outstanding (Diluted)1.36B

Key Highlights

  • 1Total revenues increased by 56% year-over-year to $929.2 million in Q2 2024.
  • 2BRUKINSA global sales grew by 107% year-over-year to $637.4 million in Q2 2024.
  • 3U.S. BRUKINSA sales grew by 114.4% year-over-year to $479.4 million in Q2 2024.
  • 4GAAP net loss for the quarter was $120.4 million, a significant improvement from $381.1 million in Q2 2023.
  • 5GAAP loss from operations narrowed to $107.2 million, an improvement from $318.7 million in Q2 2023.
  • 6Collaboration revenue decreased by 81% year-over-year to $8.0 million.
  • 7The company opened its flagship U.S. facility in Hopewell, New Jersey.

Frequently Asked Questions

The primary driver of Beigene's revenue growth in the second quarter of 2024 is the significant increase in sales of its internally developed oncology medicine, BRUKINSA. Global sales of BRUKINSA increased by 107% year-over-year, reaching $637.4 million, propelled by strong performance in key markets like the U.S. and Europe.

Beigene ended the quarter with $2.6 billion in cash, cash equivalents, and restricted cash, providing a solid liquidity position. While the company continues to incur net losses ($120.4 million in Q2 2024), this represents a substantial improvement compared to the prior year's quarter. The company expects its existing cash to fund operations for at least the next 12 months, but it also has significant short-term debt obligations totaling over $851 million due within the next year, which it anticipates refinancing.

Research and Development (R&D) expenses increased by 7.5% to $454.5 million for the three months ended June 30, 2024, compared to the same period in 2023, driven by increased Amgen co-development expenses and development milestone fees. Selling, General, and Administrative (SG&A) expenses also increased by 12.3% to $443.7 million, primarily due to investments in expanding commercial activities to support product launches. Despite these increases, SG&A expenses as a percentage of product sales decreased significantly, indicating improved operational leverage.